



April 10, 2026

Company name: Nippon Soda Co., Ltd.
Name of representative: Eiji Aga
Representative Director and President
(Securities code: 4041; TSE Prime Market)
Inquiries: Toyonobu Katagishi
Manager of General Affairs Dept.
(Telephone: +81-3-6366-1920)

**Nippon Soda Co., Ltd. and Hokkaido University Commence
Joint Research Collaboration
-Research and Development of Veterinary Pharmaceuticals-**

Nippon Soda Co., Ltd. (hereinafter "the Company") is pleased to announce the commencement of a joint research collaboration with the Institute for Vaccine Research and Development (IVReD) at Hokkaido University's Institute for Integrated Innovations, and the Faculty of Veterinary Medicine, Hokkaido University. The collaboration agreement was signed on Friday, March 13, 2026, to pursue the research and development of novel veterinary pharmaceuticals. This joint research aims to develop novel veterinary medicinal products and establish commercial-scale manufacturing processes.

1. Scope of Joint Research

Leveraging the extensive expertise of the Faculty of Veterinary Medicine, this collaborative research initiative will bring together IVReD and the Company to design novel veterinary pharmaceuticals and establish commercial-scale manufacturing processes. Furthermore, safety studies for the developed antibodies, as well as clinical studies in diseased animals, are planned to be conducted at the Hokkaido University Veterinary Teaching Hospital and other veterinary medical facilities.

2. Research Period

March 13, 2026 – March 31, 2027

The Company's mission is to create new value through the power of chemistry and increase corporate value by contributing to society. Through this joint research collaboration with Hokkaido University, the Company aims to contribute to solving social issues related to healthcare and achieve sustainable growth of the Nippon Soda Group.